These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma. Dimitrova V; Arcaro A Curr Mol Med; 2015; 15(1):82-93. PubMed ID: 25601471 [TBL] [Abstract][Full Text] [Related]
26. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup. Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068 [TBL] [Abstract][Full Text] [Related]
27. Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib. Lou E; Schomaker M; Wilson JD; Ahrens M; Dolan M; Nelson AC Cancer Biol Ther; 2016 Oct; 17(10):1010-1016. PubMed ID: 27682250 [TBL] [Abstract][Full Text] [Related]
28. Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. Robson JP; Remke M; Kool M; Julian E; Korshunov A; Pfister SM; Osborne GW; Taylor MD; Wainwright B; Reynolds BA PLoS One; 2019; 14(1):e0210665. PubMed ID: 30657775 [TBL] [Abstract][Full Text] [Related]
29. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738 [TBL] [Abstract][Full Text] [Related]
32. SHH inhibitors for the treatment of medulloblastoma. Samkari A; White J; Packer R Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634 [TBL] [Abstract][Full Text] [Related]
33. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach. Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673 [TBL] [Abstract][Full Text] [Related]
34. A simplified approach using Taqman low-density array for medulloblastoma subgrouping. Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734 [TBL] [Abstract][Full Text] [Related]
35. Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours. Łastowska M; Jurkiewicz E; Trubicka J; Daszkiewicz P; Drogosiewicz M; Malczyk K; Grajkowska W; Matyja E; Cukrowska B; Pronicki M; Perek-Polnik M; Perek D; Dembowska-Bagińska B J Neurooncol; 2015 May; 123(1):65-73. PubMed ID: 25862008 [TBL] [Abstract][Full Text] [Related]
36. Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. Zou H; Poore B; Broniscer A; Pollack IF; Hu B Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164294 [TBL] [Abstract][Full Text] [Related]
37. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
38. Medulloblastoma: Molecular understanding, treatment evolution, and new developments. Liu X; Ding C; Tan W; Zhang A Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673 [TBL] [Abstract][Full Text] [Related]